Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point
Immunology & Cell Biology · 2026-11 · 104 (10) · 1015-1018
DOI: 10.1111/imcb.70169 ↗At a glance
Übersichtsarbeit in Immunology & Cell Biology, published online on 2026-10-06. Written by Rowena A Bull and 1 co-authors. Institution: School of Biomedical Sciences, UNSW Sydney, Kensington, New South Wales, Australia. Major MEDLINE topics: AIDS Vaccines, HIV Antibodies, Germ Cells, HIV Infections. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: UNSW Faculty of Medicine, UNSW Triple I Seed Grant, Hillcrest Foundation and Perpetual Impact.
Abstract (original language)
This commentary examines three recent Nature studies demonstrating a conceptual shift in HIV vaccine design, demonstrating how germline-targeting HIV vaccines can progress beyond expanding rare broad neutralizing antibody (bnAb) precursors to deliberately guiding their affinity maturation into bnAbs in non-human primates.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Biomedical Sciences, UNSW Sydney, Kensington, New South Wales, Australia.
- The Kirby Institute, UNSW Sydney, Kensington, New South Wales, Australia.
- Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
ORCID profiles: Rowena A Bull, Deborah L Burnett
Funding
- UNSW Faculty of Medicine
- UNSW Triple I Seed Grant
- Hillcrest Foundation and Perpetual Impact
- Australian National Health and Medical Research Council (NHMRC)
- National Health and Medical Research Council
Cite
APA
Bull, R. A., & Burnett, D. L. (2026). Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point. Immunology & Cell Biology, 104(10), 1015-1018. https://doi.org/10.1111/imcb.70169
Vancouver
Bull RA, Burnett DL. Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point. Immunology & Cell Biology. 2026;104(10):1015-1018. doi:10.1111/imcb.70169
BibTeX
@article{Bull2026,
author = {Bull, Rowena A and Burnett, Deborah L},
title = {Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point},
journal = {Immunology & Cell Biology},
year = {2026},
volume = {104},
number = {10},
pages = {1015--1018},
doi = {10.1111/imcb.70169}
}
EUVIMED